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ABSTRACT 
We describe the synthesis and characterization of ametantrone-containing RNA ligands based on 
the derivatization of this intercalator with two neamine moieties (Amt-Nea,Nea) or with one 
azaquinolone heterocycle and one neamine (Amt-Nea,Azq), as well as its combination with 
guanidinoneamine (Amt-NeaG4). Biophysical studies revealed that guanidinylation of the parent 
ligand (Amt-Nea) had a positive effect on the binding of the resulting compound for Tau pre-
mRNA target, as well as on the stabilization upon complexation of some of the mutated RNA 
sequences associated with the development of tauopathies. Further studies by NMR revealed the 
existence of a preferred binding site in the stem-loop structure, in which ametantrone intercalates 
in the characteristic bulged region. Regarding doubly-functionalized ligands, binding affinity and 
stabilizing ability of Amt-Nea,Nea were similar to those of the guanidinylated ligand, but the two 
aminoglycoside fragments seem to interfere with its accommodation in a single binding site. 
However, Amt-Nea,Azq binds at the bulged region in a similar way than Amt-NeaG4. Overall, 
these results provide new insights on how fine-tuning RNA binding properties of ametantrone by 
single or double derivatization with other RNA recognition motifs, which could help in the future 
to the design of new ligands with improved selectivity for disease-causing RNA molecules. 
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INTRODUCTION 
The search for drugs based on small molecules to control RNA function has been postulated in 
recent years as a promising strategy to treat human diseases.1 This is supported by the great 
biological relevance of both coding and non-coding RNA molecules,2 and by the fact that only a 
small number of the proteins linked to genetic diseases can be targetable with drug-like 
compounds.3 In addition, the folding of local secondary structures of therapeutically relevant 
RNA targets into complex three dimensional architectures offers the possibility, like in proteins, 
of using ligands for targeting specific binding sites in a selective manner.4 However, despite the 
great potential of RNA as a drug target, finding selective ligands for a specific sequence and with 
drug-like properties still remains a challenge. The high conformational dynamics of this 
biomolecule together with our limited understanding of ligand-RNA recognition principles 
difficult the de novo design of selective RNA ligands.5 Within this scenario, the modification of 
known building blocks by using fragment-based approaches6 offers an alternative for developing 
compounds with improved RNA-binding properties (e.g. affinity, sequence specificity and 
cellular permeability), as well as for gaining knowledge on RNA recognition mechanisms.  
Among the large number of RNA ligands described in the literature so far, the anticancer drug 
mitoxantrone (Mtx in Scheme 1) has received attention recently. This classical nucleic acid 
intercalator was identified in a high-throughput screening as a promising ligand7 of the RNA 
secondary structure located at the exon 10-5’ intron junction of Tau pre-mRNA, which is 
involved in the regulation of the alternative splicing of tau protein.8 According to NMR structural 
data,7b this compound intercalates between the two G:C pairs flanking the bulged adenine in the 
stem-loop structure of Tau. In addition, the two side arms of the anthraquinone moiety play an 
important role in the recognition of this characteristic binding site. Mitoxantrone also binds HIV-
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1 transactivation response element (TAR) RNA with nM affinity, although non-specific binding 
was also found in competition assays with tRNA.9 
Taking into account our previous results on Tau RNA ligands based on the combination of 
acridines with the small aminoglycoside neamine,10 we recently focused on a derivative of 
mitoxantrone lacking the phenolic hydroxyl groups. This heteroaromatic compound, known as 
ametantrone (Amt in Scheme 1), was selected because of its proven reduced cytotoxicity in 
eukaryotic cells compared with mitoxantrone.11 Dynamic combinatorial chemistry together with 
biophysical experiments demonstrated that the combination of ametantrone with neamine led to 
ligands with high binding affinity (nM scale for Tau RNA), particularly when both moieties were 
conjugated through a short spacer (Amt-Nea in Scheme 1).12 NMR spectroscopic studies of the 
complex between this compound and Tau RNA revealed the existence of a preferred binding site 
in which ametantrone intercalates in the bulged region of the stem-loop structure and the neamine 
moiety and the Amt side chains interact with the major groove of the RNA. Importantly, Amt-
Nea was able to increase the thermodynamic stability of Tau RNA mutated sequences involved in 
the onset of frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17)8 to 
a similar or even higher levels than that of the wild-type sequence. The stabilization of Tau RNA 
mutated sequences upon ligand complexation could be used to modulate Tau pre-mRNA splicing 
and, for instance, to counteract the negative effects of dementia-causing mutations.7,8 Moreover, 
the presence of the characteristic bulged adenine nucleotide flanked by G:C pairs in other 
therapeutically relevant RNA targets, such as the Rev response element (RRE) RNA, opens the 
door to the development of selective ligands for this RNA motif based on Mtx/Amt derivatives.13 
On the basis of all these precedents, we wondered how derivatization of the free side arm of the 
anthraquinone moiety in Amt-Nea (Scheme 1) could affect its Tau RNA-binding properties, 
particularly binding affinity and stabilizing ability against FTDP-17-causing mutations, as well as 
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to assess if the preferred binding site at the bulged region is maintained. Here we report the 
synthesis and Tau RNA binding studies of ligands (Scheme 1) based on the derivatization of 
ametantrone with two neamine moieties (Amt-Nea,Nea) or with one neamine and one 
azaquinolone (Amt-Nea,Azq). The azaquinolone moiety was selected because of the potential of 
this heteroaromatic compound to recognize the bulged adenine in the stem-loop via 
complementary hydrogen bonding pairing.14 The guanidinylated analogue of Amt-Nea (named 
Amt-NeaG4) was also included in this study, since guanidinylation has proved to be a promising 
approach to improve RNA-binding properties of aminoglycoside-containing compounds as well 
as their cellular uptake.10b,15 
 
 
Scheme 1. (A) Structure of mitoxantrone and ametantrone. (B) Schematic representation of ligands based 
on the derivatization of ametantrone through one or the two side chains of the anthraquinone ring. 
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RESULTS AND DISCUSSION 
Synthesis of Amt-containing ligands. 
The synthesis of second generation ametantrone-containing ligands (Amt-NeaG4, Amt-Nea,Nea 
and Amt-Nea,Azq; Scheme 1) was planned in solution by using thiol-disulfide exchange 
reactions mediated by 2,2′-dithiobis-(5-nitropyridine) (DTNP).12,15,16 For this purpose, two 
ametantrone derivatives were prepared in which one or the two hydroxyl groups of the side 
chains of the anthraquinone heterocycle were replaced by thiol functions masked as thioacetyl (2 
and 3, respectively, see Scheme 2). First, reaction of 1,4-difluoroanthraquinone with an excess of 
N-(2-hydroxyethyl)ethylenediamine afforded ametantrone, whose secondary alkyl amino 
functions were selectively Boc protected to afford intermediate 1.12 After Mitsunobu reaction 
with DIAD, PPh3 and thiolacetic acid, the mono- (2, 36%) and bis-thioacetyl (3, 59%) derivatives 
were isolated by silica column chromatography and fully characterized by NMR and MS.  
 
Scheme 2. Synthesis of Boc-protected ametantrone derivatives 2 and 3. 
 
For the synthesis of the guanidinylated analogue of Amt-Nea, we used N,N′-di-Boc-N″-
triflylguanidine, since we and others have demonstrated previously the utility of this reagent to 
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transform amino groups into guanidinium in compounds incorporating aminoglycoside fragments 
such as neamine or neomycin.10b,15,17 To avoid possible side-reactions with the two alkyl 
secondary amino functions of the anthraquinone moiety during guanidinylation, we decided to 
keep them masked with the Boc group (Scheme 3). First, the thiol-containing neamine derivative 
410 was activated with DTNP under acidic conditions overnight under an Ar atmosphere. 
Reaction of intermediate 5 with the thiol derivative of bis-Boc-protected ametantrone 6,12 which 
was easily prepared by hydrolysis of the thioester group of 2 with sodium methoxide, afforded 
the expected disulfide intermediate 7 after purification by reversed-phase HPLC. Finally, reaction 
of 7 with N,N′-di-Boc-N″-triflylguanidine in the presence of triethylamine followed by acidic 
deprotection with a TFA cocktail containing triisopropylsilane as cation scavenger, afforded the 
trifluoroacetate salt of the desired compound as a dark blue solid after purification by HPLC and 
lyophilisation (yield 64%). Amt-NeaG4 was fully characterized by NMR (1D 1H, COSY, 
TOCSY) and high-resolution ESI mass spectrometry. Despite the prolonged reaction time (14 
days) and the use of a large excess of the guanidinylating reagent (up to 360-fold molar 
equivalent), the triguanidinylated derivative was also identified in the reaction crude (see Figure 
S1 in the Supporting Information), which can be attributed to the steric hindrance caused by the 
Boc groups in the anthraquinone moiety. 
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Scheme 3. Synthesis of the guanidinylated ligand Amt-NeaG4. 
 
As shown in Scheme 4, a similar approach was used for the synthesis of doubly-functionalized 
amentantrone-containing ligands. In this case, the Boc protected derivative of ametantrone 
containing one thioacetyl group at each side chain was used (3). After hydrolysis of the two 
thioester groups with sodium methoxide, the thiol derivative 8 was reacted with an excess of the 
activated neamine 4 under slightly acidic conditions during 5 days at room temperature. The Boc-
protected intermediate, Amt(Boc)2-Nea,Nea was treated with TFA/TIS/H2O 95:2.5:2.5 for 1 h at 
room temperature and the expected ligand, Amt-Nea,Nea, was isolated by HPLC with an overall 
6% yield. Regarding the synthesis of the compound containing three different RNA-binding 
moieties, the thiol-containing ametantrone derivative 8 was reacted simultaneously with activated 
neamine (5) and activated azaquinolone (9)12 derivatives. After TFA treatment, Amt-Nea,Azq 
was isolated by HPLC and characterized by MS and NMR (overall yield 8%). The formation of 
several side-products (e.g. Amt-Nea,Nea and Amt-Azq,Azq during the synthesis of Amt-
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Nea,Azq) due to lack of selectivity during the formation of disulfide bonds accounts for the low 
yield in both cases (see HPLC traces of the crudes in Figure S1 in the Supporting Information).  
 
Scheme 4. Synthesis of the doubly-functionalized ligands, Amt-Nea,Nea (A) and Amt-Nea,Azq (B).  
 
Biophysical studies on the interaction of Amt-containing ligands with Tau RNA. 
Our next objective was to study the interaction of the new ametantrone-containing ligands (Amt-
NeaG4 , Amt-Nea,Nea and Amt-Nea,Azq) with Tau RNA, and in particular to assess how the 
modifications introduced in the parent Amt-Nea ligand (e.g. guanidinylation or double 
functionalization) influence RNA binding affinity as well as their ability to stabilize the disease-
causing mutated sequences.8 First, quantitative binding studies were carried out by fluorescence 
titration experiments by using 5’-end fluorescein-labelled wt RNA. As shown in Figure 1, the 
oligoribonucleotide fluorescence was quenched upon addition of increasing concentrations of the 
ligands, which reproduce the tendency previously found with other Tau RNA ligands containing 
heteroaromatic moieties.7b,10,12 A characteristic dose-dependent curve was obtained when the 
normalized fluorescence was plotted in front of the compound concentration. The inherent 
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fluorescence of the ligands was always subtracted from that of the labelled RNA by repeating the 
full titration in the absence of RNA. This approach allows the determination of EC50 values (the 
effective ligand concentration required for 50% RNA response) by fitting the data to a sigmoidal 
dose-response curve (Figure 1).  
 
Figure 1. (A) Sequences and secondary structure of wild-type (wt) and of some mutated Tau stem-loop 
RNAs (+3, +13, +14 and +16). Exonic sequences are shown in capital letters and intronic sequences in 
lower case. Nucleotides involved in base pairs, previously identified by NMR, are connected by a 
dash.7b,8b An asterisk denotes 2’-O-methyl modification. In fluorescence binding experiments, fluorescein 
derivatization was performed at the 5’ end. (B) Fluorescence quenching of wt Tau RNA labelled with 
fluorescein upon addition of increasing concentrations of Amt-NeaG4. Experimental conditions: [RNA] = 
25 nM and [ligand] = 0 to 614 nM, in 10 mM sodium phosphate buffer pH 6.8, 100 mM NaCl and 0.1 mM 
Na2EDTA. (C) Plot of the normalized fluorescence signal at 517 nm against the log of the ligand 
concentration. The normalized fluorescence was calculated by dividing the difference between the 
observed fluorescence, F’, and the final fluorescence, Ff, by the difference between the initial 
fluorescence, F0, and the final fluorescence, Ff. 
 
 
A C B 
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The EC50 values of the new ametantrone-containing ligands together with those of ametantrone, 
mitoxantrone, neamine and guanidinoneamine are shown in Table 1. EC50 values of the Amt-Nea 
and Amt-Azq ligands have also been included for comparison purposes.12 Consistent with our 
previous results,10b,15 the guanidinylation of the neamine moiety had a positive effect on the 
binding affinity of Amt-Nea. Indeed, the EC50 value for Amt-NeaG4 was about 1.2 times lower 
than for the parent amino ligand (e.g. EC50 = 57.2 + 2.0 nM for Amt-NeaG4 vs. EC50 = 70.6 + 7.2 
nM for Amt-Nea). The opposite tendency was found when a second fragment (neamine or 
azaquinolone) was incorporated in the free side chain of ametantrone in Amt-Nea: the EC50 
values for Amt-Nea,Nea and for Amt-Nea,Azq were 1.1 and 1.2 times higher than for Amt-Nea, 
respectively. However, it is worth noting that the affinity of both doubly-functionalized ligands is 
still higher higher than that of ametantrone, thereby suggesting that, upon ligand complexation, 
the two RNA binding moieties attached to the anthraquinone intercalator might participate in the 
interaction with the RNA target.  
Fluorescence binding assays were repeated in the presence of a biologically relevant competitor 
(a tRNAmix from baker’s yeast) to get some insights on their specificity for Tau RNA. As shown 
in Table 1, the specificity of the ligands was highly dependent on the nature of the modification 
introduced in the parent ligand. In the presence of the competitor, the EC50 value of Amt-NeaG4 
for Tau RNA was increased by 10-fold, whereas those of Amt-Nea,Nea and Amt-Nea,Azq were 
increased by about 7-fold. Hence, guanidinylation of the neamine moiety in Amt-Nea seems to 
have a negative effect on the specificity compared with the introduction of a second RNA binding 
moiety. The fact that all ametantrone ligands containing one or two neamine moieties or 
guanidinoneamine are less specific than the parent anthraquinone building blocks (Mtx or Amt) 
or Amt-Azq is in agreement with the known promiscuity of aminoglycosides and their 
derivatives. 
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Table 1. Binding of the ligands to wt RNA in the absence or in the presence of a tRNA competitor. 
 
 
 
 
 
 
 
 
 
 
aAll fluorescence measurements were performed in 10 mM sodium phosphate buffer pH 6.8, 100 mM 
NaCl and 0.1 mM Na2EDTA. bMeasured in the presence of a 30-fold nucleotide excess of a mixture of 
tRNA (tRNAmix). cEC50 values of these ligands12 have been included in the table for comparison purposes. 
Next, we investigated the ability of second generation Amt-containing ligands to stabilize Tau 
RNA, in particular some of the mutated sequences found in patients suffering from tauopathies 
like FTDP-17. These intronic mutations (denoted as +3, +13, +14 and +16 in Figure 1) are known 
to decrease the thermodynamic stability of the stem-loop structure located at the exon 10-5’ 
intron junction of Tau pre-mRNA.8 As previously stated, reversing the destabilization of these 
mutated sequences upon ligand complexation has been postulated as a therapeutic tool to restore 
the physiological balance of tau isoforms generated upon abnormal alternative splicing and, for 
instance, as a potential treatment for such neurodegenerative diseases.  
Ligand EC50 (nM)a EC50 (nM) 
+tRNAb 
EC50+tRNA 
/ EC50  
    
Neamine 3.1x106 nd nd 
Guanidinoneamine 830 nd nd 
Mitoxantrone 168.8 + 6.2 803.3 4.8 
Ametantrone 231.8 + 8.0 675.6 2.9 
Amt-Azqc 162.5 + 5.7 570.7 3.5 
Amt-Neac 70.6 + 7.2 569.8 8.1 
Amt-NeaG4 57.2 + 2.0 580.1 10.2 
Amt-Nea,Nea 76.2 + 4.1 519.7 6.8 
Amt-Nea,Azq 84.5 + 3.8 558.6 6.6 
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UV melting experiments were carried out by monitoring the absorbance as a function of 
temperature. The midpoint of the transition (see Figures S2-S5 in the Supporting Information) is 
referred to as the melting temperature (Tm), and provides an indicative of the thermal stability of 
the RNA secondary structure in the presence of a given ligand. As shown in Table 2, 
guanidinylation of Amt-Nea had a positive effect on the thermal stability of wt RNA upon 
complexation (∆TmG = +3.1oC; ∆TmG indicates the effect of guanidinylation compared with that 
of the parent non-guanidinylated ligand, Amt-Nea). This effect was similar with the +14 mutated 
sequence (∆TmG = +2.4oC) but slightly lower with the +16 mutant (∆TmG = +0.7oC). However, 
the stabilizing effect of Amt-NeaG4 upon complexation with the +3 mutated RNA (∆TmG = -
1.3oC) was lower than in the presence of Amt-Nea, but still substantially higher (∆Tm = +11.6oC) 
compared with that of Amt (∆Tm = +2.8oC) or Mtx (∆Tm = +5.7oC) with this mutated sequence. 
Regarding doubly-functionalized ligands, the tendency was found to be the opposite depending 
on the nature of the second moiety attached to the anthraquinone fragment in the Amt-Nea 
ligand, neamine or azaquinolone. As shown in Table 2, the effect of Amt-Nea,Nea on the thermal 
stability of all RNA sequences was always higher than that of the parent ligand. This increase 
was particularly high for the wt (∆Tm = +8.9oC with Amt-Nea vs. ∆Tm = +13oC with Amt-
Nea,Nea) and the +14 mutant (∆Tm = +10.4oC with Amt-Nea vs. ∆Tm = +14.4oC with Amt-
Nea,Nea). However, the stabilization induced by Amt-Nea,Azq was considerably lower than that 
of Amt-Nea. Such differences were particularly important with wt RNA (∆Tm = +8.9oC with 
Amt-Nea vs. ∆Tm = +4.7oC with Amt-Nea,Azq) and with the +3 mutated sequence (∆Tm = 
+12.9oC with Amt-Nea vs. ∆Tm = +6.8oC with Amt-Nea,Azq). These results are quite surprising 
because EC50 values of Amt-Nea,Nea and Amt-Nea,Azq point to similar binding affinities for 
Tau RNA. Despite this reduced stabilizing ability, the neamine moiety in Amt-Nea,Azq still 
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seems to have a positive effect on the thermal stabilization of the RNAs upon complexation, as 
inferred from the higher Tm values of its complexes compared with those obtained in the presence 
of Amt-Azq 
Table 2. Melting temperatures (Tm) for the complexation of the ligands with Tau RNAs (1 µM both in 
RNA and in ligands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl and 0.1 mM Na2EDTA).  
 
 
 
 
 
 
 
 
 
 
 
 
a
∆Tm= (Tm of the RNA in the presence of ligand) – (Tm of RNA alone).  
 
Spectroscopic studies on the interaction of Amt-containing ligands with Tau RNA. 
The overall biophysical studies indicated that both binding affinity and stabilizing ability of the 
parent Amt-Nea ligand are influenced either by guanidinylation of the aminoglycoside moiety or 
by functionalization of the second arm of ametantrone. Hence, our next objective was focused on 
investigating the effect of these ligands (Amt-NeaG4, Amt-Nea,Nea and Amt-Nea,Azq) on the 
structure of Tau RNA upon complexation, and in particular to determine if they also have a 
 Tm wt ∆Tma Tm ∆Tma Tm ∆Tma Tm ∆Tma 
         No ligand 66.5 - 51.4 - 53.5 - 59.6  
Neamine 66.9 +0.4 51.5 +0.1 54.0 +0.5 60.1 +0.5 
Guanidinoneamine 67.7 +1.2 52.8 +1.4 54.5 +1.0 61.0 +1.4 
Mitoxantrone 69.2 +2.7 57.1 +5.7 58.1 +4.6 63.4 +3.8 
Ametantrone 67.1 +0.5 54.2 +2.8 55.7 +2.2 61.6 +2.0 
Amt-Azq 67.8 +1.3 56.1 +4.7 57.3 +3.8 61.8 +2.2 
Amt-Nea 75.4 +8.9 64.3 +12.9 63.9 +10.4 69.4 +9.8 
Amt-NeaG4 78.5 +12.0 63.0 +11.6 66.3 +12.8 70.1 +10.5 
Amt-Nea,Nea 79.5 +13.0 67.0 +15.6 67.9 +14.4 70.8 +11.2 
Amt-Nea,Azq 71.2 +4.7 58.2 +6.8 61.1 +7.6 66.3 +6.7 
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preferred binding site. As previously stated, intercalation of the anthraquinone moiety in the 
bulged region of the stem-loop structure of Tau RNA together with specific contacts between the 
positively-charged side chains and the neamine moiety with the RNA, account for the high 
binding affinity and stabilizing ability of Amt-Nea.12  
First, fluorescence emission spectra (upon excitation at 547 nm) were recorded for the three 
compounds in the absence and in the presence of increasing amounts of wt Tau RNA. As shown 
in Figure 2, hypochromic and bathochromic effects were observed in the fluorescence spectra of 
the ligands during the titration with RNA, although those effects were more pronounced in the 
case of Amt-NeaG4 and Amt-Nea,Nea, which is consistent with a higher binding affinity. 
Interestingly, a strong hypochromism was observed in the fluorescence spectra of these ligands in 
the first stage of the titration (0.07 mol equiv. of RNA for Amt-NeaG4 and 0.17 mol equiv. of 
RNA for Amt-Nea,Nea). Then, in the second stage of the titration, the intensity of the 
fluorescence emission band increased gradually until saturation was reached, and then decreased 
again. In both cases, an 8 nm shift to higher wavelengths was observed (from the initial 656 nm 
band in the free ligand). These results reproduced those previously observed for mitoxantrone8b 
and for the parent Amt-Nea ligand,12 and suggest that neither guanidinylation nor double 
functionalization of ametantrone with two neamine moieties seem to difficult the intercalation of 
the anthraquinone fragment. Although this two-stage binding mode was not completely 
reproduced in the case of Amt–Nea,Azq, which could be attributed to a lower binding affinity 
compared with that of the Amt-NeaG4 or Amt-Nea,Nea, the quenching of the fluorescence 
intensity points also to the intercalation of the ametantrone fragment. 
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Figure 2. Fluorescence emission spectra of Amt-NeaG4 (A), Amt-Nea,Nea (B) and Amt-Nea,Azq (C) in 
the absence and in the presence of increasing amounts of wt RNA in a 10 mM sodium phosphate buffer, 
pH 6.8, containing 100 mM NaCl and 0.1 mM Na2EDTA. 2 µM solutions of the ligands were used in 
fluorescence titration experiments. The emission spectra were recorded from 600 ~ 850 nm with λex = 547 
nm. 
 
Although qualitative information on the interaction of heteroaromatic compounds with nucleic 
acids can be obtained from UV-Vis or fluorescence spectroscopy,18 these techniques do not 
provide detailed structural information on their binding mode, which is necessary to rationalize 
their RNA-binding properties and, more importantly, to help in the design of more selective 
ligands with improved ones. In this context, NMR spectroscopy is a powerful technique to detect 
A B 
C 
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RNA-ligand interactions, particularly in the case of ligands based on the combination of 
fragments.19 
Titration experiments of Tau RNA with ametantrone-containing ligands (Amt-NeaG4, Amt-
Nea,Nea and Amt-Nea,Azq) were monitored by NMR spectroscopy (see Figure 3 and Figure S6 
in the Supporting Information) to get more detailed information on their mode of interaction. 
Interestingly, a similar behaviour to that previously found with the parent ligand Amt-Nea12 was 
observed upon addition of either Amt-NeaG4 or Amt-Nea,Azq (see the exchangeable proton 
region of the NMR spectra in Figure 3), including little line broadening and changes in the 
chemical shifts of some imino protons of the RNA close to the bulged region. The co-existence of 
imino signals arising from the free and bound RNA at a RNA:ligand ratio of 1:0.5 indicates that 
both species are in slow equilibrium in the NMR time scale. Moreover, the fact that only one set 
of signals at a 1:1 ratio was observed suggests that Amt-NeaG4 and Amt-Nea,Azq bind Tau RNA 
in a well defined binding site. As shown in Figure 3, imino signals of the complex between Tau 
RNA and the ligands at a 1:1 ratio were labelled according to previously reported data from the 
complex Tau-Amt-Nea due to their similar behaviour during the titration.12 In both cases, the 
most pronounced changes in chemical shifts involved the imino proton of G-1 (see Figure 3 for 
the labelling of the imino protons), which was shifted by about –0.85 ppm upon complexation 
with Amt-NeG4 or Amt-Nea,Azq, compared with their values in the free RNA. In contrast, the 
effect of Amt-Nea,Azq on the imino signal of U0 was much higher than that provoked by Amt-
NeaG4 (+0.35 and +0.13 ppm, respectively), and in both cases imino signals of G+1, U+2 and 
G+3 were not significantly affected in the complexes. As previously found with Amt-Nea, 
appearance of an imino signal which was assigned to G+17 confirms the allocation of both 
ligands at the bulged region of the stem-loop structure, particularly of the amentatrone fragment 
which would protect the C-3:G+17 base pair from the solvent in the complex. In addition, the two 
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signals in the exchangeable proton region (δ ≈ 9.9 and 9.5 ppm) corresponding to the aliphatic 
amino protons of the two side chains of the ametantrone moiety of the ligand were clearly 
observed upon complexation with Amt-NeaG4 or Amt-Nea,Azq, suggesting again a similar 
binding mode to that described for Amt-Nea.12 
To our surprise, addition of Amt-Nea,Nea caused a general line broadening of all signals together 
with major changes in the chemical shifts of the imino protons of the RNA (see Figure 3). The 
fact that two set of signals corresponding to the aliphatic amino protons of the ametantrone 
moiety of the ligand were observed upon complexation (δ ≈ 9.9 and 9.4 ppm, and δ ≈ 10.5 and 
10.6 ppm) suggests the presence of two binding sites for this ligand in Tau RNA. Hence, besides 
allocation at the bulged region of Tau RNA, the presence of two neamine fragments seems to 
direct the binding of Amt-Nea,Nea to another region of the stem-loop structure, probably at the 
loop or at the major groove. In addition, the large number of signals at the imino proton region 
also suggests weak aggregation as a consequence of the complexation of Tau RNA with Amt-
Nea,Nea. 
 
 19
 
 
U+11
G-1
G+3
G+5
U0
U+2 G+1
14 13 12 11 10 ppm
1:0
1:1.5
1:1
1:0.5
RNA:ligand ratio
NH Amt
G-1
G+3
G+1
G+17U0
U+2
B
 
 
U+11
G-1
G+3
G+5
U0
U+2 G+1
14 13 12 11 10 ppm
1:0
1:1.5
1:1
1:0.5
RNA:ligand ratio
NH AmtG-1 G+3G+1 G+17U0 U+2
C
 
U+11
G-1
G+3
G+5
U0 U+2
G+1
14 13 12 11 10 ppm
1:0
1:1.5
1:1
1:0.5
RNA:ligand ratio
NH Amt
D
 
Figure 3. Secondary structure of wt Tau RNA sequence showing the labelling of the characteristic imino 
signals (A) and imino region of the NMR spectra of the oligoribonucleotide alone and in the presence of 
increasing amounts of the ligands, Amt-NeaG4 (B), Amt-Nea,Azq (C) or Amt-Nea,Nea (D). From bottom 
to top: ligand/RNA ratio = 0.0, 0.5, 1.0 and 1.5. Assignments for the RNA alone are labelled according to 
previously reported works.7b,8b,12 Imino signals at RNA/ligand ratio 1:1 are labelled according to the 
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complex between Tau RNA and Amt-Nea.12 Experimental conditions: [RNA]= 70 µM, 10 mM phosphate 
buffer in H2O/D2O 90:10, pH= 6.8, T=5ºC. 
 
CONCLUSIONS 
In summary, in this work we have described two new Tau RNA ligands based on the 
derivatization of ametantrone with two neamine moieties (Amt-Nea,Nea) or with one 
azaquinolone heterocycle and one neamine moiety (Amt-Nea,Azq), with the aim of exploring 
how functionalization of the two side chains of this anthraquinone intercalator affects RNA-
binding properties. A guanidinylated ligand based on the derivatization of ametantrone with a 
single guanidinoneamine moiety (Amt-NeaG4) was also synthesized. Biophysical studies have 
demonstrated that these compounds bind Tau RNA with high affinity, particularly the 
guanidinylated derivative (EC50 = 57.2 nM), and that the double functionalization of ametantrone 
does not conduce to a significant decrease in their binding affinity (only about 1.1-1.2 fold) when 
compared with the parent ligand (Amt-Nea). In addition, all the compounds cause a significant 
increase in the thermal stability of Tau RNA, particularly Amt-NeaG4 and Amt-Nea,Nea (∆Tm 
=+12 and +13 ºC, respectively). Interestingly, these compounds are able to restore the 
thermodynamic stability of some of the mutated sequences associated with the development of 
FTDP-17 disease to a higher level than that of wt RNA, which is of high relevance for 
developing potential modulators of Tau pre-mRNA splicing. For example, the Tm value of the 
+16 mutated sequence when complexed with these ligands was about 4ºC higher than that of wt 
RNA alone. Finally, NMR titration experiments revealed that Amt-NeaG4 and Amt-Nea,Azq 
have a preferred binding site in the stem-loop structure of Tau RNA, in which ametantrone 
intercalates in the bulged region, thereby indicating that conjugation with guanidinoneamine or 
with neamine and azaquinolone does not seem to modify the preference of this anthraquinone 
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derivative for this region. Although attachment of two aminoglycoside moieties conduce to a 
ligand with promising RNA-binding properties, the lack of a preferred binding site in the RNA 
target discards Amt-Nea,Nea as a lead compound for further developing RNA ligands for 
regulating the alternative splicing of Tau pre-mRNA. All together the present work reported here 
provides new insights for designing ligands based on amentantrone with improved RNA-binding 
properties. Current efforts are aimed at exploring the use of these and other amentantrone-
containing derivatives as ligands of other therapeutically relevant RNA secondary structures 
involved in the onset of human diseases. 
 
EXPERIMENTAL SECTION 
Materials and Methods. Unless otherwise stated, common chemicals and solvents (HPLC grade 
or reagent grade quality) were purchased from commercial sources and used without further 
purification. Aluminium plates coated with a 0.2 mm thick layer of silica gel 60 F254 were used 
for thin-layer chromatography analyses (TLC), whereas flash column chromatography 
purification was carried out using silica gel 60 (230-400 mesh).  
Reversed-phase high-performance liquid chromatography (HPLC) analyses of the ligands and 
their precursors were carried out on a Jupiter Proteo C18 column (250x4.6 mm, 90 Å 4 µm, flow 
rate: 1 mL/min) using linear gradients of 0.045% TFA in H2O (A) and 0.036% TFA in ACN (B). 
In some cases, purification was carried out using the same analytical column. A semipreparative 
Jupiter Proteo column was used for the purification of some compounds (250x10 mm, 90 Å 10 
µm, flow rate: 3 mL/min), using linear gradients of 0.1% TFA in H2O (A) and 0.1% TFA in ACN 
(B). 
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NMR spectra were recorded at 25ºC in a 600 MHz spectrometer using deuterated solvents. The 
residual signal of the solvent was used as a reference in 1H spectra. Chemical shifts are reported 
in part per million (ppm) in the δ scale, coupling constants in Hz and multiplicity as follows: s 
(singlet), d (doublet), t (triplet), q (quadruplet), qt (quintuplet), m (multiplet), dd (doublet of 
doublets), td (doublet of triplets), ddd (doublet of doublet of doublets), br (broad signal). 
High-resolution matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
spectra were recorded both in positive (2,4-dihydroxybenzoic acid matrix) or negative mode 
(2,4,6-trihydroxyacetophenone matrix with ammonium citrate as an additive). Electrospray 
ionization mass spectra (ESI-MS) were recorded on an instrument equipped with single 
quadrupole detector coupled to an HPLC, and high-resolution (HR) ESI-MS on LC/MS-TOF 
instrument. 
Oligoribonucleotides were synthesized on a DNA automatic synthesizer (1-µmol scale) using 2’-
O-tert-butyldimethylsilyl protection and following standard procedures (phosphite triester 
approach). RNA and fluorescein phosphoramidites, solid-supports, reagents and solvents for 
oligoribonucleotide synthesis were purchased from Glen Research or Link Technologies. RNase-
free reagents, solutions and materials were used when manipulating oligoribonucleotides. RNase-
free water was obtained directly from a Milli-Q system equipped with a 5000-Da ultrafiltration 
cartridge.  
Reversed-phase HPLC was used for the analysis and purification of the oligoribonucleotides 
using linear gradients of 0.1 M aqueous NH4HCO3, and a 1:1 mixture of 0.1 M aqueous 
NH4HCO3 and ACN. A Kromasil C18 column (250x4.6 mm, 10 µm, flow rate: 1 mL/min) was 
used for RNA analysis whereas a semipreparative Jupiter C18 column (250x10 mm, 300 Å 10 
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µm, flow rate: 3 mL/min) was used for purification at large scale. Characterization was carried 
out by high resolution MALDI-TOF MS (negative mode, THAP matrix with ammonium citrate). 
 
Synthesis of ametantrone-containing ligands. 
Amt-NeaG4. First, 2,2’-dithiobis(5-nitropyridine) (11.6 mg, 37.5 µmol) and the neamine thiol 
monomer 4 (3 µmol) were reacted in a 2:1 (v/v) mixture of THF/aqueous 0.1 % TFA (2 mL) 
under argon at RT. After 17 h, THF was evaporated in vacuo and the remaining yellow solution 
was diluted with H2O (2 mL). The aqueous phase was washed with AcOEt to remove the excess 
2,2′-dithiobis(5-nitropyridine) (typically 6×2 mL or until no yellow colour was detected in the 
organic phase) and lyophilized to afford activated neamine 5. Second, to a stirred solution of 
thioacetyl derivative 2 (2.4 mg, 3.6 µmol) in MeOH (1 mL) was added sodium methoxide (24 
µL, 1 M in MeOH, 24 µmol) and the mixture stirred for 5 min at RT under argon. After 
evaporation in vacuo, the crude containing thiol amentantrone derivative 6 was dissolved in 
H2O/ACN 8:2 (v/v) containing 0.1% TFA (8 mL) and added over the activated neamine 5, and 
the mixture was stirred overnight under argon at RT. After purification by semipreparative 
reversed-phase HPLC (linear gradient from 0 to 80% B in 35 min; A, 0.1% TFA in H2O; B, 0.1% 
TFA in ACN; Rt = 21 min) and lyophilization, the TFA salt of Amt(Boc)2-Nea (7) was obtained 
as a blue solid (0.48 mg, yield 11%).  
Compound 7 (400 nmol) and 1,3-di-Boc-2-trifluoromethylsulfonyl)guanidine (12.5 mg, 32 µmol) 
were dissolved in a 5:3 (v/v) mixture of MeOH and CHCl3 (2 mL) under argon. Then, 
triethylamine (27 µL, 192 µmol) was added and the reaction mixture was stirred for 14 days at 
RT under Ar. A total of 360 mol equiv. of guanidinylating reagent and of 1680 mol equiv. of 
triethylamine was added over the entire reaction period. After evaporation in vacuo, the crude 
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was diluted with DCM (5 mL) and washed with a 10% aqueous solution of citric acid (3×1 mL) 
and with brine (3×1 mL). The organic phase was taken up and dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo to dryness. The crude product was dissolved in a 1:1 (v/v) 
mixture of TFA and DCM containing 2.5% of TIS (2 mL). After it was stirred at RT for 2 h 
under Ar, the mixture was diluted with toluene (2 mL) and evaporated in vacuo. After several 
coevaporations from toluene, the residue was dissolved in Milli-Q H2O (5 mL) and lyophilized to 
provide a blue solid. Purification was carried out by analytical reversed-phase HPLC (linear 
gradient from 0 to 30% B in 35 min; A, 0.045% TFA in H2O; B, 0.036% TFA in ACN), and the 
TFA salt of the desired product was obtained after lyophilisation (0.43 mg, yield 64% from 7). 1H 
NMR (600 MHz, D2O) δ (ppm): 8.31 (2H, H6+H7 Amt, m), 7.86 (2H, H5+H8 Amt, m), 7.58 (2H, 
H2+H3 Amt, m), 5.58 (1H, H1’, d, J = 3.6 Hz), 4.08 (1H, -S-CH2-CH2-O-, m), 3.92 (2H, -NH-
CH2-CH2-OH, t, J = 6.4 Hz), 3.84 (4H, -NH-CH2-CH2-NH-CH2-, t, J = 5.3 Hz), 3.81 (1H, H5’, 
m), 3.77 (1H, -S-CH2-CH2-O-, m), 3.70 (2H, -NH-CH2-CH2-S-, m), 3.68-3-58 (5H, H2’, H4’, H4, 
H5, H6), 3.50-3.43 (5H, H1, H3, H3’, -NH-CH2-CH2-S-, m), 3.40 (2H, -NH-CH2-CH2-OH, m), 
3.20 (4H, -NH-CH2-CH2-NH-CH2-, m), 2.89 (2H, H6’, m), 2.77 (2H, -S-CH2-CH2-O-, m), 2.21 
(1H, H2,eq, m), 1.62 (1H, H2,ax, m); HR-ESI MS, positive mode: m/z 977.4553 (calcd mass for 
C40H65N16O9S2 [M+H]+: 977.4562), m/z 489.2313 (calcd mass for C40H66N16O9S2 [M+2H]2+: 
489.2320), m/z 326.4905 (calcd mass for C40H67N16O9S2 [M+3H]3+: 326.4906); analytical HPLC 
(linear gradient from 0 to 30% B in 30 min): Rt = 24.4 min. 
Amt-Nea,Nea. First, the thiol function of the neamine derivative 4 (7 µmol) was activated by 
reaction with DTNP (27.2 mg, 87.5 µmol) in a 2:1 (v/v) mixture of THF/aqueous 0.1 % TFA (8 
mL) under argon at RT for 17 h. After evaporation in vacuo, excess of DTNP was eliminated and 
the crude containing 5 was lyophilized. Second, to a stirred solution of the bis-thioester derivative 
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3 (1.4 mg, 1.9 µmol) in MeOH (1 mL) was added sodium methoxide (190 µL, 0.1 M in MeOH, 
19 µmol) and the mixture stirred for 5 min at RT under argon. After evaporation in vacuo, the 
crude containing bis-thiol amentantrone derivative 8 was dissolved in H2O/ACN 8:2 (v/v) 
containing 0.1% TFA (10 mL) and added over the activated neamine 5, and the mixture was 
stirred for 5 days under argon at RT. After purification by analytical reversed-phase HPLC (linear 
gradient from 0 to 80% B in 35 min; A, 0.045% TFA in H2O; B, 0.036% TFA in ACN; Rt = 18 
min) and lyophilization, the TFA salt of Amt(Boc)2-Nea,Nea was obtained. Finally, treatment 
with TFA/TIS/H2O 95:2.5:2.5 (1 mL) for 1 h at RT afforded the TFA salt of Amt-Nea,Nea as a 
blue solid after HPLC purification (0.27 mg, yield 6%). 1H NMR (600 MHz, D2O) δ (ppm): 8.32 
(2H, H6+H7 Amt, m), 7.89 (2H, H5+H8 Amt, m), 7.56 (2H, H2+H3 Amt, m), 5.62 (2H, H1’, m), 
4.15 (2H, -S-CH2-CH2-O-, m), 3.98 (6H, H5’, H6, -S-CH2-CH2-O-, m), 3.93 (4H, -NH-CH2-CH2-
NH-CH2-, t, J = 6.0 Hz), 3.80 (2H, H3’), 3.70 (4H, H4, H5, m), 3.61 (2H, H4’, m), 3.46 (8H, -NH-
CH2-CH2-NH-CH2-, m), 3.40 (4H, H6’, m), 3.20 (4H, H1, H3, m), 3.12 (2H, H2’, m), 3.02 (4H, 
NH-CH2-CH2-S-, t, J = 6.8 Hz), 2.92 (4H, -S-CH2-CH2-O-, t, J=6.3 Hz), 2.23 (2H, H2,eq, m), 1.56 
(2H, H2,ax, m); HR-ESI MS, positive mode: m/z 1205.5241 (calcd mass for C50H85N12O14S4 
[M+H]+: 1205.5191), m/z 603.2642 (calcd mass for C50H86N12O14S4 [M+2H]2+ : 603.2635), m/z 
402.5122 (calcd mass for C50H87N12O14S4 [M+3H]3+: 402.5116); analytical HPLC (linear 
gradient from 0 to 30% B in 30 min): Rt = 22.7 min. 
Amt-Nea,Azq. First, the thiol functions of neamine (1.5 µmol) and of azaquinolone monomers10 
(3 µmol) were activated with DTNP (5.8 mg, 18.8 µmol and 11.6 mg, 37.5 µmol, respectively) in 
a 2:1 (v/v) mixture of THF/aqueous 0.1 % TFA (1.5 and 2 mL, respectively) under argon at RT 
for 17 h. After evaporation in vacuo, excess of DTNP was eliminated and both activated 
derivatives were isolated by semipreparative reversed-phase HPLC (linear gradient from 0 to 
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80% B in 30 min; A, 0.1% TFA in H2O; B, 0.1% TFA in ACN; Rt = 14.1 min for 5 and Rt = 17.9 
min for 9). Second, to a stirred solution of 3 (1 mg, 1.4 µmol) in MeOH (1 mL) was added 
sodium methoxide (275 µL, 0.1 M in MeOH, 27.5 µmol) and the mixture stirred for 5 min at RT 
under argon. After evaporation in vacuo, the crude containing derivative 8 was dissolved in 
H2O/ACN 8:2 (v/v) containing 0.1% TFA (12 mL) and added over activated monomers 5 and 9, 
and the mixture was stirred for 6 days under argon at RT. After purification by analytical 
reversed-phase HPLC (linear gradient from 0 to 80% B in 35 min; A, 0.045% TFA in H2O; B, 
0.036% TFA in ACN; Rt = 20.5 min) and lyophilization, the TFA salt of Amt(Boc)2-Nea,Azq 
was obtained. Finally, treatment with TFA/TIS/H2O 95:2.5:2.5 (1 mL) for 1 h at RT afforded the 
TFA salt of Amt-Nea,Azq as a blue solid after HPLC purification (0.21 mg, yield 8%). 1H NMR 
(600 MHz, D2O) δ (ppm): 7.95 (2H, H6+H7 Amt, m), 7.65 (2H, H5+H8 Amt, m), 7.57 (1H, H5 
Azq, d, J = 7.8 Hz), 7.53 (1H, H4 Azq, d, J = 9.5 Hz), 7.33 (2H, H2+H3 Amt, m), 6.80 (1H, H6 
Azq, d, J = 7.8 Hz), 6.30 (1H, H3 Azq, d, J = 9.5 Hz), 5.35 (1H, H1’, m), 4.01 (2H, CH2 Azq, s), 
3.88-3.72 (7H, -S-CH2-CH2-O-, -NH-CH2-CH2-NH-, H5’, m), 3.43-3.10 (16H, H4, H5, H6, H2’, 
H3’, H4’, -CO-NH-CH2-CH2-CH2-NH-, -NH-CH2-CH2-S-, m), 3.08-2.97 (4H, H1, H3, H6’, m), 
2.95 (2H, -CO-NH-CH2-CH2-CH2-NH-, t, J = 7.9 Hz), 2.90 (2H, -NH-CH2-CH2-S-, t, J = 6.3 
Hz), 2.85 (2H, -NH-CH2-CH2-S-, t, J = 6.3 Hz), 2.81 (2H, -S-CH2-CH2-CO-NH-, t, J = 6.4 Hz), 
2.72 (2H, -S-CH2-CH2-O-, m), 2.52 (2H, -S-CH2-CH2-CO-NH-, t, J = 6.4 Hz), 2.02 (1H, H2,eq, 
m), 1.79 (2H, -CO-NH-CH2-CH2-CH2-NH-, m), 1.38 (1H, H2,ax, m); HR-ESI MS, positive mode: 
m/z 1143.4599 (calcd mass for C51H75N12O10S4 [M+H]+: 1143.4612), m/z 572.2334 (calcd mass 
for C51H76N12O10S4 [M+2H]2+ : 572.2345), m/z 381.8250 (calcd mass for C51H77N12O10S4 
[M+3H]3+: 381.8256); analytical HPLC (linear gradient from 5 to 35% B in 35 min): Rt = 22.8 
min. 
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